We show for the first time that human breast, prostate, and ovarian cancer cell lines express measureable levels of Tie2, and that treatment of these cells with the preclinical versions of Trebananib (mL4-3 and L1-7 (N)), which are selective peptibodies that inhibit the binding of Ang1 and Ang2 to Tie2, mediates immunogenic modulation, rendering tumor cells more susceptible to T cell-mediated killing. The gene discussed is TEK; the disease is ovarian cancer.